HIV drugs News and Research

RSS

New guidelines for managing chronic kidney disease in patients living with HIV infection

The HIV Medicine Association has released guidelines for managing chronic kidney disease in patients living with HIV infection. They are published in the June 1 issue of Clinical Infectious Diseases.

27 Apr 2005

HIV treatment-experienced patients set high standards for therapy success

Patients who have previously failed at least two anti-HIV regimens continue to have high standards for their treatment success, according to a survey commissioned by the American Foundation for AIDS Research (amfAR).

11 Apr 2005

Panel in US disputes drug trial allegations

Medical experts have been forced to defend a study conducted in Uganda and called HIVNET 012 that led to the widespread use of a single AIDS drug called nevirapine to protect newborns, after allegations by Dr. Jonathan Fishbein, a National Institutes of Health researcher, that the research was flawed and the conclusions were unfounded.

10 Apr 2005

Test of new HIV drug

A study under way at UAB aims to determine whether the first of a new class of HIV drugs is safe and effective in preventing the virus from entering healthy cells.

10 Apr 2005

AIDS virus initially more destructive than first thought

The AIDS virus destroys more than half of the immune cells that might recognize and help fight it, within days of infection according to US researchers, and this revelation might necessitate a re-evaluation of how the deadly infection should be tackled.

28 Mar 2005

Research could lead to new drugs that combat HIV infection by shutting down the virus's assembly lines

After infecting a susceptible cell, the human immunodeficiency virus hijacks that cell's normal machinery to produce carbon copies of itself. New HIV particles roll off the cellular assembly lines, burst like bubbles out of the cell, and float off to invade other cellular factories.

14 Mar 2005

Government should plough drug savings into Pharmaceutical Benefits Scheme (PBS)

Doctors and medicine-makers today called for an expected $280 million Pharmaceutical Benefits Scheme (PBS) windfall to be ploughed into bringing down the price of new cancer and HIV drugs.

9 Jan 2005

New technique could lead to more effective therapies for AIDS

When researchers came up with the powerful cocktail of anti-HIV drugs known as highly active antiretroviral therapy (HAART), they hoped they had found a way to finally rid the body of the virus. But they were wrong.

4 Jan 2005

Scientists have identified a novel anti-tuberculosis (TB) compound

Scientists at Johnson & Johnson Pharmaceutical Research and Development have identified a novel anti-tuberculosis (TB) compound that works better and faster than the current standard of care in mouse models of TB infection.

14 Dec 2004

HIV drugs known as protease inhibitors also protect against Malaria

Scientists from The Queensland Institute of Medical Research (QIMR) have found that a group of HIV drugs known as protease inhibitors may also be effective for treating or preventing malaria.

11 Nov 2004

Cellular enzyme represents a potential new target for developing improved HIV drugs

Scientists have discovered that a cellular enzyme helps ferry HIV genetic instructions out of the cell nucleus where they can then be translated into proteins to begin their most destructive work.

1 Nov 2004

A new general medical journal launched this week with a non-traditional publishing model

A new general medical journal launched this week with a non-traditional publishing model is the latest top-tier venue for publishing important, peer-reviewed biomedical research, and is being called the first major, international journal to be introduced in more than 70 years.

22 Oct 2004

One group of drugs that is effective in fighting HIV may also be promoting the death of sensory nerves in the skin

One group of drugs that is effective in fighting HIV may, paradoxically, also be promoting the death of sensory nerves in the skin, according to a study presented October 5, 2004, at the 129th annual meeting of the American Neurological Association in Toronto.

5 Oct 2004

Peginterferon and Ribavirin combination promising for those with HIV and HCV

Since the introduction of highly active combination drug therapy for HIV, liver failure attributable to infection with the hepatitis C virus (HCV) has become a leading cause of death among those infected with the virus that causes AIDS.

22 Aug 2004

Study shows safe, effective therapy for previously untreated patients with HIV & hepatitis C

An international study with nearly 900 patients co-infected with Human Immunodeficiency Virus (HIV) and hepatitis C virus (HCV) has shown that HCV can be treated effectively and safely, without compromising the patient’s HIV therapy.

29 Jul 2004

Mothers infected with HIV who breast feed risk infecting infants

After four weeks of age, infants who breast feed from mothers infected with HIV continue to be at risk for infection with HIV for as long as they breastfeed

17 Jun 2004

Weekly cycles of once-daily anti-HIV drugs could reduce cost of HIV treatment

24 May 2004

Weekly cycles of once-daily anti-drugs could reduce cost of HIV treatment

In a small study conducted at the U.S. National Institutes of Health (NIH), researchers have shown that it may be feasible to treat HIV-infected patients with a simple, once-daily regimen of anti-HIV drugs given in pre-planned, 7-day-on, 7-day-off cycles. This approach is known formally as “short-cycle structured intermittent antiretroviral therapy” (SIT) or colloquially as the “7-7” approach.

20 May 2004

Plans for once-daily, fixed-dose combination of three anti-HIV drugs

Bristol-Myers Squibb Company, Gilead Sciences, Inc. and Merck & Co., Inc. have announced that they are in discussions on the development of a once-daily, fixed-dose combination of three anti-HIV drugs and are also considering certain co-packaging options for the individual products.

16 May 2004